Familial defective apolipoprotein B-100 in hypercholesterolemic Chinese Canadians: identification of a unique haplotype of the apolipoprotein B-100 allele. 1997

L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
Department of Pathology, University of British Columbia, Vancouver, Canada.

Familial defective apo B-100 (FDB) is an autosomal dominant condition resulting in hypercholesterolemia. It is generally observed in 1-6% of hypercholesterolemic subjects in Caucasian populations studied. There are, thus far, no reports characterizing the frequency and phenotype of FDB in a Chinese population. We report on the frequency of the FDB (Arg(3500)--> Gln) mutation and the associated haplotype among 160 hypercholesterolemic (TC > or = 6.2 mmol/l) Chinese Canadians including 36 subjects with a clinical diagnosis of familial hypercholesterolemia (FH). Screening for the FDB mutation was done using a mutagenic polymerase chain reaction and haplotype analysis was undertaken using eight diallelic markers and the 3'HVR marker. One Chinese Canadian clinical FH heterozygote was positive for the FDB Arg(3500)--> Gln mutation while none of the remaining non-FH hypercholesterolemic subjects (n = 124) were carriers of this mutation. Haplotype analysis in the patient positive for this mutation revealed a unique haplotype which differed from both the common haplotype of this mutation observed in Caucasians and from the only other haplotype reported in a Chinese individual. The associated haplotype included a 9-base pair deletion in the signal peptide region and the presence of three restriction sites absent in previously reported haplotypes. These data suggest that the apo B-100 Arg(3500)--> Gln mutation does not appear to be a significant factor contributing to moderate hypercholesterolemia in a Chinese population residing in Canada. However, this mutation was rarely observed among Chinese individuals with a clinical diagnosis of FH. The presence among Chinese individuals of two different haplotypes associated with this mutation, which are different from what has been described among Caucasians is compatible with multiple recurrent origins for this mutation in the Chinese population.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006239 Haplotypes The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX. Haplotype
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
July 1993, Journal of lipid research,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
January 1998, Ryoikibetsu shokogun shirizu,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
September 1998, Danish medical bulletin,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
June 1991, Atherosclerosis,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
January 2016, Journal of clinical lipidology,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
October 2000, Atherosclerosis,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
July 2007, Nihon rinsho. Japanese journal of clinical medicine,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
September 2001, Clinical and experimental medicine,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
October 2007, Atherosclerosis,
L O Abdel-Wareth, and S N Pimstone, and J P Lagarde, and A Raisonnier, and P Benlian, and H Pritchard, and M R Hayden, and J J Frohlich
May 1991, Klinische Wochenschrift,
Copied contents to your clipboard!